A minimally Invasive surgical platform aGainst paNcreatIc and biliary Tract cancErs using cold atmospheric PLASMA

癌症是欧洲主要的死亡原因之一。胰腺（PC）和胆道（BTC）癌是罕见的胃肠道腺癌，发病率不断增加，特别是在老年人和老年欧洲人口中的妇女中，预后不良构成了重大的临床挑战和公共卫生负担。冷大气压等离子体（CAP）在实验室环境中显示出潜在的消退各种癌症类型。由于其性质，CAP是高浓度反应性自由基、电子、离子、UV等的独特来源，其可在活组织中诱导各种效应。CAP在治疗癌细胞时显示出对健康细胞影响最小的选择性;这使得血浆适用于治疗非常敏感区域或器官中的癌症，其中存在未满足的最小化损伤/副作用的需求。CAP可以通过不同长度的电介质管输送，这使其成为微创和精确腹腔镜和内窥镜手术的理想选择。尽管这一概念具有巨大的前景和潜力，但目前市场上还没有基于CAP治疗癌症的单一腹腔镜或内窥镜医疗平台。该项目提出了一种新的解决方案，使用尖端的等离子体技术，硅模型和系统级方法。它将联合收割机等离子体与肿瘤多尺度模拟相结合，并将从术前诊断中获取输入，用于计算机模型初始化和CAP操作窗口确定。开发的技术将通过体内实验进行演示，而该项目将为PC/BTC的CAP护理的临床试验和市场引入奠定基础。

Cancer is one of the major causes of death in Europe. Pancreatic (PC) and biliary tract (BTC) cancer are rare gastrointestinal adenocarcinomas with an increasing incidence particularly among the elderly and women in an ageing European population, and a poor prognosis poses major clinical challenges and public health burden. Cold atmospheric pressure plasma (CAP) has shown potential regressing various cancer types in the laboratory setting. Owing to their properties, CAP is a unique source of high concentrations of reactive radicals, electrons, ions, UV etc. that may induce various effects in living tissue. CAP has shown selectivity in where cancer cells are treated with minimal effect to healthy ones; this renders plasma suitable to treat carcinomas in very sensitive areas or organs where an unmet need to minimise damage/side-effects exists. CAP can be delivered through dielectric tubes of variable length, which makes it ideal for minimally invasive and precise laparoscopic and endoscopic operations. Despite the great promise and potential of this concept, there is no single laparoscopic or endoscopic medical platform in the market today based on CAP to treat carcinomas. This project proposes a novel solution using cutting-edge plasma technology, in-silico models, and a system-level approach. It will combine plasma with tumour multiscale simulations and will take input from pre-surgery diagnostics for in-silico model initialisation and CAP operational window determination. The developed technology will be demonstrated through in-vivo experiments, while the foundations for clinical trials and market introduction for CAP-based care of PC/BTCs will be laid out in this project.